A Phase I, Randomized, Placebo-Controlled, Observer-blind, Two-dose (0-28 Day Schedule) Primary Vaccination Study of Walter Reed Army Institute of Research (WRAIR) Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) in Healthy Adults in a Non-Endemic Region
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs TDENV PIV (Primary) ; Aluminium hydroxide; AS01E; AS03B
- Indications Dengue
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms DPIV-001
- 08 Aug 2018 Status changed from active, no longer recruiting to completed.
- 02 May 2018 Planned End Date changed from 1 Feb 2018 to 1 Sep 2018.
- 04 Apr 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.